Formulated for major depressive disorder to manage emotional health and support cognitive symptom relief.
Mechanism of Action
Vortioxetine acts by inhibiting the reuptake of serotonin and modulating several serotonin receptors (antagonism at 5-HT3 and 5-HT7, agonism at 5-HT1A). This multimodal activity enhances serotonergic neurotransmission and improves mood and focus.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
66 hours (half-life)
Contraindications
Concurrent use of MAO inhibitors, Hypersensitivity to vortioxetine
Severe Adverse Events
Serotonin syndrome, Suicidal ideation, Hyponatremia — requires immediate medical attention
Common Side Effects
Nausea, Diarrhea, Dry mouth
Uncommon Side Effects
Constipation, Dizziness, Vomiting
Drug Interactions
Alcohol, MAO Inhibitors, Warfarin, Tramadol, Rifampin
Pregnancy Safety Warnings
FDA Category C: Benefit must justify risk. Breastfeeding: Excreted in milk; monitor infant.
Age Restrictions
Safety and efficacy in pediatric patients have not been established.
Information related to Trintellix is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
